Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive December 1, 2010 Walter Armstrong	Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources.
Pharmaceutical Executive October 1, 2014 Jill Wechsler	Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak.
Chemistry World January 29, 2015 Matthew Gunther	Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study.
Chemistry World October 23, 2014 Rebecca Trager	US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences
The Motley Fool December 4, 2006 Brian Lawler	Success for Dynavax Solid results from the first of three phase III trials cause the biopharmaceutical Dynavax's shares to rise.
Chemistry World January 19, 2015 Maria Burke	Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine.
BusinessWeek April 26, 2004 Kerry Capell	Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
The Motley Fool June 12, 2006 Nathan Parmelee	Investing World Cup: Developed Asia Rebuttal Ten or 12 years from now, things might be different, but this is 2006, and developed Asia wins this one.
The Motley Fool March 7, 2011 Brian Orelli	Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues.
The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
The Motley Fool March 1, 2011 Brian Orelli	Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker.
Chemistry World August 5, 2015 Emma Stoye	Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated.
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
The Motley Fool June 16, 2006 Nathan Parmelee	Investing World Cup: Developed Asia Yes, the developed countries of Asia are filled with many well-known names that many investors follow, but that doesn't mean there aren't plenty of bargains to be had.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
Scientific American April 10, 2006 Christine Soares	Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
Pharmaceutical Executive February 1, 2009 Joanna Breitstein	Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
Scientific American November 2008 Jessica Wapner	Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation
The Motley Fool May 22, 2007 Mike Havrilla	An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
Chemistry World December 3, 2014 Maria Burke	Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline.
BusinessWeek January 29, 2007 Kerry Capell	GlaxoSmithKline: Getting AIDS Drugs To More Sick People GlaxoSmithKline sells 90% of its vaccines, in volume terms, at not-for-profit prices to customers in the developing world.
The Motley Fool September 28, 2006 Brian Lawler	Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens.
The Motley Fool May 31, 2006 Stephen D. Simpson	Vical Gets a Helping Hand Japan's AnGes MG's Allovectin-7 vaccine is now a risk-free lottery ticket for Vical. If phase 3 trials show adequate efficacy, there's upside. If the trials fail, Vical really doesn't lose much of anything. Investors, take note.
Chemistry World October 9, 2013 Phillip Broadwith	GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months.
Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
American Family Physician July 1, 2004 Lo Re & Gluckman	Travel Immunizations The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before trip departure, and current knowledge of the epidemiology of vaccine-preventable diseases.
Chemistry World March 17, 2011 Hepeng Jia	International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation.
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?
Chemistry World July 29, 2015 Maria Burke	Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear.
BusinessWeek November 18, 2010 Jason Gale	Bill Gates' Latest Challenge: Polio Bill Gates is brokering deals with drugmakers to make cheaper vaccines available.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
The Motley Fool September 7, 2005 Stephen D. Simpson	Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note.
Chemistry World August 20, 2014 Maria Burke	Doctors turn to experimental Ebola treatments The emergency use of an experimental medicine is highly unusual, but the WHO has declared the Ebola outbreak a public health emergency of international concern.
The Motley Fool October 28, 2005 Rich Duprey	Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract.
Pharmaceutical Executive July 10, 2014 Fitzpatrick & Mohan	Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance.
The Motley Fool April 6, 2010 Brian Orelli	Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
American Family Physician May 15, 2001	Pneumococcal Conjugate Vaccine: What a Parent Needs to Know Why should my child get this vaccine?... What exactly is the pneumococcal vaccine?... Are there some children who should not get pneumococcal conjugate vaccine or who should wait until they are older?...
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.